Strategies for the discovery, identification and validation of milk protein-derived bioactive peptides

Trends in Food Science and Technology

Volumn 50, Issue , 2016, Pages 26-43

  Nongonierma, Alice B ^a   FitzGerald, Richard J ^a  

^a UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

Bioactive peptides; Drug discovery; Human studies; In silico; Milk proteins; Quantitative structure activity relationship (QSAR)

Indexed keywords

COMPUTATIONAL CHEMISTRY; PEPTIDES;

BIOACTIVE PEPTIDES; DRUG DISCOVERY; HUMAN STUDY; IN-SILICO; MILK PROTEIN; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS;

PROTEINS;

EID: 84960540354     PISSN: 09242244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tifs.2016.01.022     Document Type: Review

References (146)

1. Aryee A.N., Boye J.I. Current and emerging trends in the formulation and manufacture of nutraceuticals and functional food products. Nutraceutical and functional food processing technology 2015, 1-63. Wiley-Blackwell, Oxford, UK. J.I. Boye (Ed.).
2. Aydin S., Aksoy A., Aydin S., Kalayci M., Yilmaz M., Kuloglu T., et al. Today's and yesterday's of pathophysiology: biochemistry of metabolic syndrome and animal models. Nutrition 2014, 30:1-9.
3. Bal dit Sollier C., Drouet L., Pignaud G., Chevallier C., Caen J., Fiat A.-M., et al. Effect of κ-casein split peptides on platelet aggregation and on thrombus formation in the guinea-pig. Thrombosis Research 1996, 81:427-437.
4. Barry C., O'Cuinn G., Harrington D., O'Callaghan D., Fitzgerald R. Debittering of a tryptic digest of bovine β-casein using porcine kidney general aminopeptidase and X-prolydipeptidyl aminopeptidase from Lactococcus lactis subsp. cremoris AM2. Journal of Food Science 2000, 65:1145-1150.
5. Bouhallab S.D., Oukhatar N.A.T., Mollé D., Henry G., Maubois J.-L., Arhan P., et al. Sensitivity of β-casein phosphopeptide-iron complex to digestive enzymes in ligated segment of rat duodenum. Journal of Nutritional Biochemistry 1999, 10:723-727.
6. Boutrou R., Gaudichon C., Dupont D., Jardin J., Airinei G., Marsset-Baglieri A., et al. Sequential release of milk protein-derived bioactive peptides in the jejunum in healthy humans. American Journal of Clinical Nutrition 2013, 97:1314-1323.
7. Boutrou R., Henry G., Sanchez-Rivera L. On the trail of milk bioactive peptides in human and animal intestinal tracts during digestion: A review 2015, 1-15. Dairy Science & Technology, Published online. 10.1007/s13594-015-0210-0.
8. Brouwer C.P.J.M., Rahman M., Welling M.M. Discovery and development of a synthetic peptide derived from lactoferrin for clinical use. Peptides 2011, 32:1953-1963.
9. Bunel V., Ouedraogo M., Nguyen A.T., Stévigny C., Duez P. Methods applied to the in vitro primary toxicology testing of natural products: state of the art, strengths, and limits. Planta Medica 2014, 80:1210-1226.
10. Bussadori S.K., Santos E.M., Guedes C.C., Motta L.J., Fernandes K.P.S., Mesquita-Ferrari R.A., et al. Cytotoxicity of casein phosphopeptides-amorphous calcium phosphate (CPP-ACP) paste. ConScientiae Saude 2010, 9:354-359.
11. de Castro R.J.S., Sato H.H. Biologically active peptides: processes for their generation, purification and identification and applications as natural additives in the food and pharmaceutical industries. Food Research International 2015, 74:185-198.
12. Cehreli S.B., Gurpinar A.O., Onur A.M., Dagli F.T. In vitro evaluation of casein phosphopeptides-amorphous calcium phosphate as a potential tooth transport medium: Viability and apoptosis in L929 fibroblasts. Dental Traumatology 2008, 24:314-319.
13. Celli G., Ghanem A., Brooks M.-L. Bioactive encapsulated powders for functional foods-a review of methods and current limitations. Food and Bioprocess Technology 2015, 8:1825-1837.
14. Chabance B., Marteau P., Rambaud J., Migliore-Samour D., Boynard M., Perrotin P., et al. Casein peptide release and passage to the blood in humans during digestion of milk or yogurt. Biochimie 1998, 80:155-165.
15. Cheung L.K.Y., Aluko R.E., Cliff M.A., Li-Chan E.C.Y. Effects of exopeptidase treatment on antihypertensive activity and taste attributes of enzymatic whey protein hydrolysates. Journal of Functional Foods 2015, 13:262-275.
16. Chichester C., Digles D., Siebes R., Loizou A., Groth P., Harland L. Drug discovery FAQs: workflows for answering multidomain drug discovery questions. Drug Discovery Today 2015, 20:399-405.
17. Cicero A., Gerocarni B., Laghi L., Borghi C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. Journal of Human Hypertension 2011, 25:425-436.
18. Contreras M.D.M., Hernández-Ledesma B., Amigo L., Martín-Álvarez P.J., Recio I. Production of antioxidant hydrolyzates from a whey protein concentrate with thermolysin: optimization by response surface methodology. LWT - Food Science and Technology 2011, 44:9-15.
19. Contreras M.D.M., Sevilla M.A., Monroy-Ruiz J., Amigo L., Gómez-Sala B., Molina E., et al. Food-grade production of an antihypertensive casein hydrolysate and resistance of active peptides to drying and storage. International Dairy Journal 2011, 21:470-476.
20. Coupland J., Hayes J. Physical approaches to masking bitter taste: lessons from food and pharmaceuticals. Pharmaceutical Research 2014, 31:2921-2939.
21. Dave L.A., Montoya C.A., Rutherfurd S.M., Moughan P.J. Gastrointestinal endogenous proteins as a source of bioactive peptides-An in silico study. PLoS One 2014, 9:e98922.
22. De Noni I., Stuknyte M., Cattaneo S. Identification of β-casomorphins 3 to 7 in cheeses and in their in vitro gastrointestinal digestates. LWT - Food Science and Technology 2015, 63:550-555.
23. Doke S.K., Dhawale S.C. Alternatives to animal testing: a review. Saudi Pharmaceutical Journal 2015, 23:223-229.
24. Dordević V., Balanč B., Belščak-Cvitanović A., Lević S., Trifković K., Kalušević A., et al. Trends in encapsulation technologies for delivery of food bioactive compounds. Food Engineering Reviews 2015, 7:452-490.
25. Doré J., Blottière H. The influence of diet on the gut microbiota and its consequences for health. Current Opinion in Biotechnology 2015, 32:195-199.
26. Dziuba B., Dziuba M. New milk protein-derived peptides with potential antimicrobial activity: an approach based on bioinformatic studies. International Journal of Molecular Sciences 2014, 15:14531-14545.
27. Dziuba M., Dziuba B., Iwaniak A. Milk proteins as precursors of bioactive peptides. Acta Scientiarum Polonorum Technologia Alimentaria 2009, 8:71-90.
28. Erba D., Ciappellano S., Testolin G. Effect of caseinphosphopeptides on inhibition of calcium intestinal absorption due to phosphate. Nutrition Research 2001, 21:649-656.
29. Erba D., Ciappellano S., Testolin G. Effect of the ratio of casein phosphopeptides to calcium (w/w) on passive calcium transport in the distal small intestine of rats. Nutrition 2002, 18:743-746.
30. Fernández-Musoles R., Castelló-Ruiz M., Arce C., Manzanares P., Ivorra M.D., Salom J.B. Antihypertensive mechanism of lactoferrin-derived peptides: angiotensin receptor blocking effect. Journal of Agricultural and Food Chemistry 2014, 62:173-181.
31. Ferrazzano G.F., Amato I., Cantile T., Sangianantoni G., Ingenito A. In vivo remineralising effect of GC Tooth Mousse on early dental enamel lesions: SEM analysis. International Dentistry Journal 2011, 61:210-216.
32. FitzGerald R.J., O'Cuinn G. Enzymatic debittering of food protein hydrolysates. Biotechnology Advances 2006, 24:234-237.
33. Foltz M., van Buren L., Klaffke W., Duchateau G.S.M.J.E. Modeling of the relationship between dipeptide structure and dipeptide stability, permeability, and ACE inhibitory activity. Journal of Food Science 2009, 74:H243-H251.
34. Foltz M., Meynen E.E., Bianco V., van Platerink C., Koning T.M.M.G., Kloek J. Angiotensin converting enzyme inhibitory peptides from a lactotripeptide-enriched milk beverage are absorbed intact into the circulation. Journal of Nutrition 2007, 137:953-958.
35. Foltz M., van der Pijl P.C., Duchateau G.S.M.J.E. Current in vitro testing of bioactive peptides is not valuable. The Journal of Nutrition 2010, 140:117-118.
36. Gaudel C., Nongonierma A.B., Maher S., Flynn S., Murray B.A., Kelly P.M., et al. A whey protein hydrolysate promotes insulinotropic activity in a clonal pancreatic β-cell line and enhances glycemic function in ob/ob mice. Journal of Nutrition 2013, 143:1109-1114.
37. Gleeson J.P., Heade J., Ryan S.M., Brayden D.J. Stability, toxicity and intestinal permeation enhancement of two food-derived antihypertensive tripeptides, Ile-Pro-Pro and Leu-Lys-Pro. Peptides 2015, 71:1-7.
38. Hackam D.G., Redelmeier D.A. Translation of research evidence from animals to humans. JAMA 2006, 296:1727-1732.
39. Hau J. Animal models for human diseases. Sourcebook of models for biomedical research 2008, 3-8. Humana Press. P.M. Conn (Ed.).
40. Hellberg S., Sjoestroem M., Skagerberg B., Wold S. Peptide quantitative structure-activity relationships, a multivariate approach. Journal of Medicinal Chemistry 1987, 30:1126-1135.
41. Hernández-Ledesma B., García-Nebot M.J., Fernández-Tomé S., Amigo L., Recio I. Dairy protein hydrolysates: peptides for health benefits. International Dairy Journal 2014, 38:82-100.
42. IDF The IDF consensus worldwide definition of the metabolic syndrome 2006, Accessed in September 2015. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf.
43. Iwaniak A., Minkiewicz P., Darewicz M., Protasiewicz M., Mogut D. Chemometrics and cheminformatics in the analysis of biologically active peptides from food sources. Journal of Functional Foods 2015, 16:334-351.
44. Jahangiri R., Soltani S., Barzegar A. A review of QSAR studies to predict activity of ACE peptide inhibitors. Pharmaceutical Sciences 2014, 20:122.
45. Jauhiainen T., Wuolle K., Vapaatalo H., Kerojoki O., Nurmela K., Lowrie C., et al. Oral absorption, tissue distribution and excretion of a radiolabelled analog of a milk-derived antihypertensive peptide, Ile-Pro-Pro, in rats. International Dairy Journal 2007, 17:1216-1223.
46. Jenssen H. Descriptors for antimicrobial peptides. Expert Opinion on Drug Discovery 2011, 6:171-184.
47. Jing P., Qian B., He Y., Zhao X., Zhang J., Zhao D., et al. Screening milk-derived antihypertensive peptides using quantitative structure activity relationship (QSAR) modelling and in vitro/in vivo studies on their bioactivity. International Dairy Journal 2014, 35:95-101.
48. Kaiser S., Martin M., Lunow D., Rudolph S., Mertten S., Möckel U., et al. Tryptophan-containing dipeptides are bioavailable and inhibit plasma human angiotensin-converting enzyme in vivo. International Dairy Journal 2016, 52:107-114.
49. Kawaguchi K., Nakamura T., Kamiie J., Takahashi T., Yamamoto N. Accumulation of ACE inhibitory tripeptides, Val-Pro-Pro and Ile-Pro-Pro, in vascular endothelial cells. Bioscience Biotechnology and Biochemistry 2012, 76:1792-1795.
50. Kim H.-O., Li-Chan E.C.Y. Quantitative structure-activity relationship study of bitter peptides. Journal of Agricultural and Food Chemistry 2006, 54:10102-10111.
51. Korpela K., Flint H.J., Johnstone A.M., Lappi J., Poutanen K., Dewulf E., et al. Gut microbiota signatures predict host and microbiota responses to dietary interventions in obese individuals. PLoS One 2014, 9:e90702.
52. Lacroix I.M., Li-Chan E.C. Comparison of the susceptibility of porcine and human dipeptidyl-peptidase IV to inhibition by protein-derived peptides. Peptides 2015, 69:19-25.
53. Lalor F., Wall P.G. Making and justifying health claims. International Journal of Dairy Technology 2013, 66:321-324.
54. Le Maux S., Nongonierma A.B., FitzGerald R.J. Improved short peptide identification using HILIC-MS/MS: retention time prediction model based on the impact of amino acid position in the peptide sequence. Food Chemistry 2015, 175:847-854.
55. Ledoux N., Mahe S., Dubarry M., Bourras M., Benamouzig R., Tome D. Intraluminal immunoreactive caseinomacropeptide after milk protein ingestion in humans. Food/Nahrung 1999, 43:196-200.
56. Lee Y.S., Noguchi T., Naito H. Intestinal absorption of calcium in rats given diets containing casein or amino acid mixture: the role of casein phosphopeptides. British Journal of Nutrition 1983, 49:67-76.
57. Leeb E., Götz A., Letzel T., Cheison S.C., Kulozik U. Influence of denaturation and aggregation of β-lactoglobulin on its tryptic hydrolysis and the release of functional peptides. Food Chemistry 2015, 187:545-554.
58. Lenton S., Nylander T., Teixeira S.M., Holt C. A review of the biology of calcium phosphate sequestration with special reference to milk. Dairy Science & Technology 2015, 95:3-14.
59. Li-Chan E.C. Bioactive peptides and protein hydrolysates: research trends and challenges for application as nutraceuticals and functional food ingredients. Current Opinion in Food Science 2015, 1:28-37.
60. Li Y.-W., Li B. Characterization of structure-antioxidant activity relationship of peptides in free radical systems using QSAR models: key sequence positions and their amino acid properties. Journal of Theoretical Biology 2013, 318:29-43.
61. Li Y.-W., Li B., He J., Qian P. Structure-activity relationship study of antioxidative peptides by QSAR modeling: the amino acid next to C-terminus affects the activity. Journal of Peptide Science 2011, 17:454-462.
62. Liu X., Jiang D., Peterson D.G. Identification of bitter peptides in whey protein hydrolysate. Journal of Agricultural and Food Chemistry 2014, 62:5719-5725.
63. López-Fandiño R., Otte J., van Camp J. Physiological, chemical and technological aspects of milk-protein-derived peptides with antihypertensive and ACE-inhibitory activity. International Dairy Journal 2006, 16:1277-1293.
64. Ma J.-J., Mao X.-Y., Wang Q., Yang S., Zhang D., Chen S.-W., et al. Effect of spray drying and freeze drying on the immunomodulatory activity, bitter taste and hygroscopicity of hydrolysate derived from whey protein concentrate. LWT-Food Science and Technology 2014, 56:296-302.
65. Maeno M., Nakamura Y., Mennear J.H., Bernard B.K. Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): III. Single-and/or repeated-dose toxicity of tripeptides containing Lactobacillus helveticus-fermented milk powder and casein hydrolysate in rats. International Journal of Toxicology 2005, 24:13-23.
66. Matoba T., Hayashi R., Hata T. Isolation of bitter peptides from tryptic hydrolysate of casein and their chemical structure. Agricultural and Biological Chemistry 1970, 34:1235-1243.
67. McGonigle P., Ruggeri B. Animal models of human disease: challenges in enabling translation. Biochemical Pharmacology 2014, 87:162-171.
68. Meisel H., Fairweather-Tait S., FitzGerald R.J., Hartmann R., Lane C.N., McDonagh D., et al. Detection of caseinophosphopeptides in the distal ileostomy fluid of human subjects. British Journal of Nutrition 2003, 89:351-358.
69. Mendanha D.V., Ortiz S.E.M., Favaro-Trindade C.S., Mauri A., Monterrey-Quintero E.S., Thomazini M. Microencapsulation of casein hydrolysate by complex coacervation with SPI/pectin. Food Research International 2009, 42:1099-1104.
70. Miner-Williams W.M., Stevens B.R., Moughan P.J. Are intact peptides absorbed from the healthy gut in the adult human?. Nutrition Research Reviews 2014, 27:308-329.
71. Morais H.A., Da Silva Barbosa C.M., Delvivo F.M., Mansur H.S., Cristina De Oliveira M., Silvestre M.P.C. Comparative study of microencapsulation of casein hydrolysates in lipospheres and liposomes. Journal of Food Biochemistry 2004, 28:21-41.
72. Moutinho C.G., Matos C.M., Teixeira J.A., Balcão V.M. Nanocarrier possibilities for functional targeting of bioactive peptides and proteins: state-of-the-art. Journal of Drug Targeting 2012, 20:114-141.
73. Mukhopadhya A., Noronha N., Bahar B., Ryan M.T., Murray B., Kelly P., et al. The anti-inflammatory potential of a moderately hydrolysed casein and its 5 kDa fraction in in vitro and ex vivo models of the gastrointestinal tract. Food & Function 2015, 6:612-621.
74. Murray B.A., Walsh D.J., FitzGerald R.J. Modification of the furanacryloyl-L-phenylalanylglycylglycine assay for determination of angiotensin-I-converting enzyme inhibitory activity. Journal of Biochemical and Biophysical Methods 2004, 59:127-137.
75. Mykkanen H.M., Wasserman R.H. Enhanced absorption of calcium by casein phosphopeptides in rachitic and normal chicks. Journal of Nutrition 1980, 110:2141-2148.
76. Naik L., Mann B., Bajaj R., Sangwan R., Sharma R. Process optimization for the production of bio-functional whey protein hydrolysates: adopting response surface methodology. International Journal of Peptide Research and Therapeutics 2013, 19:231-237.
77. Nakai S., Chan J.C., Li-Chan E.C., Dou J., Ogawa M. Homology similarity analysis of sequences of lactoferricin and its derivatives. Journal of Agricultural and Food Chemistry 2003, 51:1215-1223.
78. Nakamura Y., Yamamoto N., Sakai K., Takano T. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. Journal of Dairy Science 1995, 78:1253-1257.
79. Nelson R.W., Reusch C.E. Animal models of disease: classification and etiology of diabetes in dogs and cats. Journal of Endocrinology 2014, 222:T1-T9.
80. Nongonierma A.B., FitzGerald R.J. Biofunctional properties of caseinophosphopeptides in the oral cavity. Caries Research 2012, 46:234-267.
81. Nongonierma A.B., FitzGerald R.J. Tryptophan-containing milk protein-derived dipeptides inhibit xanthine oxidase. Peptides 2012, 37:263-272.
82. Nongonierma A.B., FitzGerald R.J. Inhibition of dipeptidyl peptidase IV (DPP-IV) by proline containing peptides. Journal of Functional Foods 2013, 5:1909-1917.
83. Nongonierma A.B., FitzGerald R.J. Bioactive properties of milk proteins in humans: a review. Peptides 2015, 73:20-34.
84. Nongonierma A.B., FitzGerald R.J. Milk proteins as a source of tryptophan-containing bioactive peptides. Food & Function 2015, 6:2115-2127.
85. Nongonierma A.B., FitzGerald R.J. The scientific evidence for the role of milk protein-derived bioactive peptides in humans: a review. Journal of Functional Foods 2015, 640:640-656.
86. Nongonierma A.B., FitzGerald R.J. Utilisation of the isobole methodology to study dietary peptide-drug and peptide-peptide interactive effects on dipeptidyl peptidase IV (DPP-IV) inhibition. Food & Function 2015, 6:312-319.
87. Nongonierma A.B., Mooney C., Shields D.C., FitzGerald R.J. Inhibition of dipeptidyl peptidase IV and xanthine oxidase by amino acids and dipeptides. Food Chemistry 2013, 141:644-653.
88. Nongonierma A.B., Mooney C., Shields D.C., FitzGerald R.J. In silico approaches to predict the potential of milk protein-derived peptides as dipeptidyl peptidase IV (DPP-IV) inhibitors. Peptides 2014, 57:43-51.
89. Norris R., Casey F., FitzGerald R.J., Shields D.C., Mooney C. Predictive modelling of angiotensin converting enzyme inhibitory dipeptides. Food Chemistry 2012, 133:1349-1354.
90. Norris R., Poyarkov A., O'Keeffe M.B., FitzGerald R.J. Characterisation of the hydrolytic specificity of Aspergillus niger derived prolyl endoproteinase on bovine β-casein and determination of ACE inhibitory activity. Food Chemistry 2014, 156:29-36.
91. O'Loughlin I.B., Murray B.A., FitzGerald R.J., Brodkorb A., Kelly P.M. Pilot-scale production of hydrolysates with altered bio-functionalities based on thermally-denatured whey protein isolate. International Dairy Journal 2014, 34:146-152.
92. Pan D., Cao J., Guo H., Zhao B. Studies on purification and the molecular mechanism of a novel ACE inhibitory peptide from whey protein hydrolysate. Food Chemistry 2012, 130:121-126.
93. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery 2010, 9:203-214.
94. Pentzien A.-K., Meisel H. Transepithelial transport and stability in blood serum of angiotensin-I-converting enzyme inhibitory dipeptides. Zeitschrift für Naturforschung C 2008, 63:451-459.
95. Pérès J.-M., Bouhallab S., Bureau F., Neuville D., Maubois J.-L., Devroede G., et al. Mechanisms of absorption of caseinophosphopeptide bound iron. Journal of Nutritional Biochemistry 1999, 10:215-222.
96. Phelan M., Aherne A., FitzGerald R.J., O'Brien N.M. Casein-derived bioactive peptides: biological effects, industrial uses, safety aspects and regulatory status. International Dairy Journal 2009, 19:634-654.
97. Picariello G., Ferranti P., Fierro O., Mamone G., Caira S., Di Luccia A., et al. Peptides surviving the simulated gastrointestinal digestion of milk proteins: biological and toxicological implications. Journal of Chromatography B 2010, 878:295-308.
98. Picariello G., Iacomino G., Mamone G., Ferranti P., Fierro O., Gianfrani C., et al. Transport across Caco-2 monolayers of peptides arising from in vitro digestion of bovine milk proteins. Food Chemistry 2013, 139:203-212.
99. van der Pijl P.C., Kies A.K., Ten Have G.A.M., Duchateau G.S.M.J.E., Deutz N.E.P. Pharmacokinetics of proline-rich tripeptides in the pig. Peptides 2008, 29:2196-2202.
100. Pinho S.C., da Silva J.C. Viability of the microencapsulation of a casein hydrolysate in lipid microparticles of cupuacu butter and stearic acid. International Journal of Food Studies 2013, 2.
101. Pripp A.H., Ardö Y. Modelling relationship between angiotensin-(I)-converting enzyme inhibition and the bitter taste of peptides. Food Chemistry 2007, 102:880-888.
102. Pripp A.H., Isaksson T., Stepaniak L., Sørhaug T. Quantitative structure-activity relationship modelling of ACE-inhibitory peptides derived from milk proteins. European Food Research and Technology 2004, 219:579-583.
103. Pripp A.H., Isaksson T., Stepaniak L., Sørhaug T., Ardö Y. Quantitative structure activity relationship modelling of peptides and proteins as a tool in food science. Trends in Food Science & Technology 2005, 16:484-494.
104. Qin C., Zhang C., Zhu F., Xu F., Chen S.Y., Zhang P., et al. Therapeutic target database update 2014: a resource for targeted therapeutics. Nucleic Acids Research 2014, 42:D1118-D1123.
105. Raikos V., Dassios T. Health-promoting properties of bioactive peptides derived from milk proteins in infant food: a review. Dairy Science & Technology 2014, 94:91-101.
106. Regazzo D., Mollé D., Gabai G., Tomé D., Dupont D., Leonil J., et al. The (193-209) 17-residues peptide of bovine β-casein is transported through Caco-2 monolayer. Molecular Nutrition & Food Research 2010, 54:1428-1435.
107. Reid G., Gaudier E., Guarner F., Huffnagle G.B., Macklaim J.M., Munoz A.M., et al. Responders and non-responders to probiotic interventions: how can we improve the odds?. Gut Microbes 2010, 1:200-204.
108. Ruiz-Giménez P., Burguete M., Castelló-Ruiz M., Marcos J.F., Salom J.B., Vallés S., et al. Bovine lactoferrin pepsin hydrolysate exerts inhibitory effect on angiotensin I-converting enzyme-dependent vasoconstriction. International Dairy Journal 2007, 17:1212-1215.
109. Ruiz-Giménez P., Ibáñez A., Salom J.B., Marcos J.F., López-Díez J.J., Vallés S., et al. Antihypertensive properties of lactoferricin B-derived peptides. Journal of Agricultural and Food Chemistry 2010, 58:6721-6727.
110. Sánchez-Rivera L., Ares I., Miralles B., Gómez-Ruiz J.Á., Recio I., Martínez-Larrañaga M.R., et al. Bioavailability and kinetics of the antihypertensive casein-derived peptide HLPLP in rats. Journal of Agricultural and Food Chemistry 2014, 62:11869-11875.
111. Sánchez-Rivera L., Santos P.F., Miralles B., Carrón R., José Montero M., Recio I. Peptide fragments from β-casein f(134-138), HLPLP, generated by the action of rat blood plasma peptidases show potent antihypertensive activity. Food Research International 2016, (in press).
112. Sato R., Noguchi T., Naito H. Casein phosphopeptide (CPP) enhances calcium absorption from the ligated segment of rat small intestine. Journal of Nutritional Science and Vitaminology 1986, 32:67-76.
113. Sawada Y., Sakamoto Y., Toh M., Ohara N., Hatanaka Y., Naka A., et al. Milk-derived peptide Val-Pro-Pro (VPP) inhibits obesity-induced adipose inflammation via an angiotensin-converting enzyme (ACE) dependent cascade. Molecular Nutrition & Food Research 2015, 59:2502-2510.
114. Shahidi F., Zhong Y. Bioactive peptides. Journal of AOAC International 2008, 91:914-931.
115. Shimizu T., Hettiarachchy N. Food-derived bioactive peptides in the market. Food proteins and peptides-Chemistry, functionality, interactions, and commercialization 2012, 375-392. CRC Press, Boca Raton, FL. N.S. Hettiarachchy, K. Sato, M.R. Marshall, A. Kannan (Eds.).
116. Shimizu M., Tsunogai M., Arai S. Transepithelial transport of oligopeptides in the human intestinal cell, Caco-2. Peptides 1997, 18:681-687.
117. Siffert W. G protein polymorphisms in hypertension, atherosclerosis, and diabetes. Annual Review of Medicine 2005, 56:17-28.
118. Spellman D., O'Cuinn G., FitzGerald R.J. Physicochemical and sensory characteristics of whey protein hydrolysates generated at different total solids levels. Journal of Dairy Research 2005, 72:138-143.
119. Spellman D., O'Cuinn G., FitzGerald R.J. Bitterness in Bacillus proteinase hydrolysates of whey proteins. Food Chemistry 2009, 114:440-446.
120. Strøm M.B., Stensen W., Svendsen J.S., Rekdal Ø. Increased antibacterial activity of 15-residue murine lactoferricin derivatives. The Journal of Peptide Research 2001, 57:127-139.
121. Stuknyte M., Cattaneo S., Masotti F., De Noni I. Occurrence and fate of ACE-inhibitor peptides in cheeses and in their digestates following in vitro static gastrointestinal digestion. Food Chemistry 2015, 168:27-33.
122. Subtil S., Rocha-Selmi G., Thomazini M., Trindade M., Netto F., Favaro-Trindade C. Effect of spray drying on the sensory and physical properties of hydrolysed casein using gum arabic as the carrier. Journal of Food Science and Technology 2014, 51.
123. Sun-Waterhouse D., Wadhwa S.S. Industry-relevant approaches for minimising the bitterness of bioactive compounds in functional foods: a review. Food and Bioprocess Technology 2013, 6:607-627.
124. Svedberg J., de Haas J., Leimenstoll G., Paul F., Teschemacher H. Demonstration of β-casomorphin immunoreactive materials in in vitro digests of bovine milk and in small intestine contents after bovine milk ingestion in adult humans. Peptides 1985, 6:825-830.
125. Ten Have G.A., van der Pijl P.C., Kies A.K., Deutz N.E. Enhanced lacto-tri-peptide bio-availability by co-ingestion of macronutrients. PloS one 2015, 10.
126. Thomson T.M., Lescarbeau R.M., Drubin D.A., Laifenfeld D., de Graaf D., Fryburg D.A., et al. Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis. BMC medical genomics 2015, 8:26.
127. Tian M., Fang B., Jiang L., Guo H., Cui J., Ren F. Structure-activity relationship of a series of antioxidant tripeptides derived from β-Lactoglobulin using QSAR modeling. Dairy Science & Technology 2015, 95:451-463.
128. Tian F., Yang L., Lv F., Yang Q., Zhou P. In silico quantitative prediction of peptides binding affinity to human MHC molecule: an intuitive quantitative structure-activity relationship approach. Amino Acids 2009, 36:535-554.
129. Townsend R.R., McFadden C.B., Ford V., Cadée J.A. A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension*. American Journal of Hypertension 2004, 17:1056-1058.
130. Tulipano G., Faggi L., Nardone A., Cocchi D., Caroli A.M. Characterisation of the potential of β-lactoglobulin and α-lactalbumin as sources of bioactive peptides affecting incretin function: In silico and in vitro comparative studies. International Dairy Journal 2015, 48:66-72.
131. Uenishi H., Kabuki T., Seto Y., Serizawa A., Nakajima H. Isolation and identification of casein-derived dipeptidyl-peptidase 4 (DPP-4)-inhibitory peptide LPQNIPPL from gouda-type cheese and its effect on plasma glucose in rats. International Dairy Journal 2012, 22:24-30.
132. Usinger L., Jensen L.T., Flambard B., Linneberg A., Ibsen H. The antihypertensive effect of fermented milk in individuals with prehypertension or borderline hypertension. Journal of Human Hypertension 2010, 24:678-683.
133. Vegarud G.E., Langsrud T., Svenning C. Mineral-binding milk proteins and peptides; occurrence, biochemical and technological characteristics. British Journal of Nutrition 2000, 84:91-98.
134. van der Velden W.J., van Iersel T.M., Blijlevens N.M., Donnelly J.P. Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Medicine 2009, 7:44.
135. van der Ven C., Gruppen H., de Bont D.B.A., Voragen A.G.J. Optimisation of the angiotensin converting enzyme inhibition by whey protein hydrolysates using response surface methodology. International Dairy Journal 2002, 12:813-820.
136. Walsh D.J., Bernard H., Murray B.A., MacDonald J., Pentzien A.K., Wright G.A., et al. In vitro generation and stability of the lactokinin β-lactoglobulin fragment (142-148). Journal of Dairy Science 2004, 87:3845-3857.
137. Wang J.-H., Liu Y.-L., Ning J.-H., Yu J., Li X.-H., Wang F.-X. Is the structural diversity of tripeptides sufficient for developing functional food additives with satisfactory multiple bioactivities?. Journal of Molecular Structure 2013, 1040:164-170.
138. Wang Z.-L., Zhang S.-S., Wang W., Feng F.-Q., Shan W.-G. A novel angiotensin I converting enzyme inhibitory peptide from the milk casein: Virtual screening and docking studies. Agricultural Sciences in China 2011, 10:463-467.
139. Watanabe M., Kurihara J., Suzuki S., Nagashima K., Hosono H., Itagaki F. The influence of dietary peptide inhibitors of angiotensin-converting enzyme on the hypotensive effects of enalapril. Journal of Pharmaceutical Health Care and Sciences 2015, (in press). 10.1186/s40780-40015-40018-40783.
140. West C.E., Renz H., Jenmalm M.C., Kozyrskyj A.L., Allen K.J., Vuillermin P., et al. The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies. Journal of Allergy and Clinical Immunology 2015, 135:3-13.
141. Wiener A., Shudler M., Levit A., Niv M.Y. BitterDB: a database of bitter compounds. Nucleic Acids Research 2012, 40:D413-D419.
142. Wu J., Aluko R.E. Quantitative structure-activity relationship study of bitter di- and tri-peptides including relationship with angiotensin I-converting enzyme inhibitory activity. Journal of Peptide Science 2007, 13:63-69.
143. Wu J., Aluko R.E., Nakai S. Structural requirements of angiotensin I-converting enzyme inhibitory peptides: quantitative structure-activity relationship study of di-and tripeptides. Journal of Agricultural and Food Chemistry 2006, 54:732-738.
144. Wu J., Aluko R.E., Nakai S. Structural requirements of angiotensin I-converting enzyme inhibitory peptides: quantitative structure-activity relationship modeling of peptides containing 4-10 amino acid residues. QSAR & Combinatorial Science 2006, 25:873-880.
145. Yamada A., Sakurai T., Ochi D., Mitsuyama E., Yamauchi K., Abe F. Antihypertensive effect of the bovine casein-derived peptide Met-Lys-Pro. Food Chemistry 2015, 172:441-446.
146. Zhou P., Liu D., Chen X., Chen Y., Labuza T.P. Stability of whey protein hydrolysate powders: effects of relative humidity and temperature. Food Chemistry 2014, 150:457-462.